Therefore, we conducted a retrospective analysis to investigate the influence of baseline, trend, and normalization of CEA on clinical outcomes including PFS and OS in patients with NSCLC and EGFR mutation. Here, CEACAM5 is linked to non-small cell lung carcinoma.